Andrew Luster
MD, PhD
Chief, Division of Rheumatology, Allergy, and Immunology
👥Biography 个人简介
Andrew Luster has been a leader in understanding chemokine-mediated neutrophil recruitment to tumors, particularly through the CXCR2/CXCL1-8 axis, and has contributed to developing CXCR2 inhibitors as cancer therapeutics. His work defined how tumor-derived CXCL chemokines create neutrophil-rich immunosuppressive microenvironments. He has demonstrated that CXCR2 blockade reduces pathological neutrophil infiltration and enhances anti-PD-1 therapy. His research on chemokine biology has been foundational for neutrophil-targeted cancer immunotherapy.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Andrew Luster 的研究动态
Follow Andrew Luster's research updates
留下邮箱，当我们发布与 Andrew Luster（Massachusetts General Hospital / Harvard Medical School）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment